Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4137328 | 0.99 | HRH3 (0.58) | HRH3RAB9A | |
| SCHEMBL524808 | 0.96 | HRH3 (0.57) | HRH3 | |
| Hydrochloric Acid SCHEMBL4131637 | 0.95 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3711691 | 0.76 | HRH3 (0.61) | HRH3 | |
| SCHEMBL20070486 | 0.75 | HRH3 (0.67) | HRH3 | |
| SCHEMBL3708963 | 0.74 | HRH3 (0.59) | HRH3 | |
| SCHEMBL524220 | 0.74 | HRH3 (1.00) | HRH3 | |
| SCHEMBL16199487 | 0.74 | HRH3 (0.58) | HRH3RAB9A | |
| Hydrochloric Acid SCHEMBL4137291 | 0.74 | HRH3 (0.58) | HRH3 | |
| SCHEMBL524345 | 0.73 | HRH3 (0.59) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | claimed |
| EP-2222664-B1 | CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-29 | — | — | EP | claimed |
| EP-2222664-A1 | CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009067401-A1 | CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | claimed |
| EP-3492451-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-3492451-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| EP-3216784-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-26 | — | — | EP | disclosed |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-9809547-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-07 | — | — | US | disclosed |
| EP-3216784-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| EP-2222664-B1 | CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-29 | — | — | EP | disclosed |
| US-8748596-B2 | Process for the preparation of histamine H3 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-02 | — | — | US | disclosed |
| WO-2009067401-A1 | CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885RAB9A 2111/4885 |
| US-10323002-B2 | Process for the preparation of histamine H3 receptor modulators | HRH3, HRH4, HRH1 | HRH3 1/4885RAB9A 1622/4885 |
| US-20180022704-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | HRH3 1/4885RAB9A 1622/4885 |
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | HRH3 1/4885RAB9A 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.